BCR-ABL1 mutation ≠ ponatinib resistance

被引:4
|
作者
Saglio, Giuseppe [1 ]
Fava, Carmen [1 ]
机构
[1] Univ Turin, I-10124 Turin, Italy
关键词
CHRONIC MYELOID-LEUKEMIA; CHROMOSOME-POSITIVE LEUKEMIAS; INHIBITOR; AP24534; POTENT;
D O I
10.1182/blood-2015-12-685149
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:666 / +
页数:2
相关论文
共 50 条
  • [31] Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
    Rea, Delphine
    Hughes, Timothy P.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 171
  • [32] T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib
    Wang, Dongmei
    Pan, Hanzhang
    Wang, Yungui
    LEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1733 - 1735
  • [33] BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
    Branford, Susan
    Yeung, David T.
    Prime, Jodi A.
    Choi, Soo-Young
    Bang, Ju-hee
    Park, Jin Eok
    Kim, Dong-Wook
    Ross, David M.
    Hughes, Timothy P.
    BLOOD, 2012, 119 (18) : 4264 - 4271
  • [34] The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
    Wylie, Andrew A.
    Schoepfer, Joseph
    Jahnke, Wolfgang
    Cowan-Jacob, Sandra W.
    Loo, Alice
    Furet, Pascal
    Marzinzik, Andreas L.
    Pelle, Xavier
    Donovan, Jerry
    Zhu, Wenjing
    Buonamici, Silvia
    Hassan, A. Quamrul
    Lombardo, Franco
    Iyer, Varsha
    Palmer, Michael
    Berellini, Giuliano
    Dodd, Stephanie
    Thohan, Sanjeev
    Bitter, Hans
    Branford, Susan
    Ross, David M.
    Hughes, Timothy P.
    Petruzzelli, Lilli
    Vanasse, K. Gary
    Warmuth, Markus
    Hofmann, Francesco
    Keen, Nicholas J.
    Sellers, William R.
    NATURE, 2017, 543 (7647) : 733 - +
  • [35] The Perplexity of Synergistic Duality: Inter-molecular Mechanisms of Communication in BCR-ABL1
    Elrashedy, Ahmed A.
    Ramharack, Pritika
    Soliman, Mahmoud E. S.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (13) : 1642 - 1650
  • [36] Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study
    Abu Seman, Zahidah
    Ahid, Fadly
    Kamaluddin, Nor Rizan
    Sahid, Ermi Neiza Mohd
    Esa, Ezalia
    Said, Siti Shahrum Muhamed
    Azman, Norazlina
    Mat, Wan Khairull Dhalila Wan
    Abdullah, Julia
    Ali, Nurul Aqilah
    Khalid, Mohd Khairul Nizam Mohd
    Yusoff, Yuslina Mat
    BMC RESEARCH NOTES, 2024, 17 (01)
  • [37] Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
    Zhang, Zhanglin
    Chen, Zhiwei
    Jiang, Mei
    Liu, Shuyuan
    Guo, Yang
    Wan, Lagen
    Li, Fei
    BMC CANCER, 2019, 19 (01)
  • [38] JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
    Aranda-Tavio, Haidee
    Recio, Carlota
    Martin-Acosta, Pedro
    Guerra-Rodriguez, Miguel
    Brito-Casillas, Yeray
    Blanco, Rosa
    Junco, Vanessa
    Leon, Javier
    Carlos Montero, Juan
    Gandullo-Sanchez, Lucia
    McNaughton-Smith, Grant
    Manuel Zapata, Juan
    Pandiella, Atanasio
    Amesty, Angel
    Estevez-Braun, Ana
    Fernandez-Perez, Leandro
    Guerra, Borja
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 144
  • [39] Identification of rare atypical BCR-ABL1 transcript: A case report
    Saha, Jayesh
    Gopinath, Vipin
    Nair, Chandran K.
    Roshan, Deepak
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (03) : 624 - 626
  • [40] Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia
    Martinez-Castillo, Macario
    Gomez-Romero, Laura
    Tovar, Hugo
    Olarte-Carrillo, Irma
    Garcia-Laguna, Anel
    Barranco-Lampon, Gilberto
    De la Cruz-Rosas, Adrian
    Martinez-Tovar, Adolfo
    Hernandez-Zavala, Araceli
    Cordova, Emilio J.
    LEUKEMIA RESEARCH, 2023, 131